Furthermore, as the BRAF WT cohort of patients are a diverse group, treatment options are much less clear cut [44, 58] although immunotherapies, as with BRAFV600E melanoma are a promising albeit costly treatment approach [59]. This evidence concerns the gene BRAF and melanoma.